C. Becker

发表

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

M. Scholz, D. Niederwieser, U. Platzbecker, 2022, Journal of Cancer Research and Clinical Oncology.

Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission

D. Niederwieser, C. Junghanss, H. Al-Ali, 2009, Leukemia.

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

D. Denning, K. Marr, T. Patterson, 2006, Journal of Infection.

Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias.

D. Niederwieser, U. Hegenbart, H. Al-Ali, 2005, Critical reviews in oncology/hematology.

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

D. Niederwieser, R. Rohrberg, R. Krahl, 2013, Journal of Cancer Research and Clinical Oncology.

Second unrelated bone marrow transplantation without additional conditioning therapy after engraftment failure

J. Edelmann, T. Friedrich, D. Wolff, 1998, Bone Marrow Transplantation.

Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)

M. Scholz, U. Platzbecker, S. Schwind, 2021, Journal of Cancer Research and Clinical Oncology.

Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia

S. Iacobelli, G. Behre, D. Niederwieser, 2014, Leukemia & lymphoma.

Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)

D. Niederwieser, R. Krahl, S. Schwind, 2017, Journal of Cancer Research and Clinical Oncology.

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

D. Niederwieser, T. Lindner, R. Krahl, 2013, Journal of Cancer Research and Clinical Oncology.

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

G. Behre, D. Niederwieser, T. Lindner, 2014, Journal of Cancer Research and Clinical Oncology.

Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma

D. Niederwieser, S. Schwind, T. Lange, 2015, Journal of Cancer Research and Clinical Oncology.

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

M. Scholz, D. Niederwieser, U. Platzbecker, 2022, Journal of Cancer Research and Clinical Oncology.

Two rare cases of bronchus‐associated lymphoid tissue lymphoma successfully treated with rituximab‐bendamustine

U. Platzbecker, N. Panitz, S. Kayser, 2021, Clinical case reports.

Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)

J. Beck, D. Niederwieser, S. Schwind, 2017, Journal of Cancer Research and Clinical Oncology.

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

D. Niederwieser, S. Scholl, C. Junghanss, 2015, Journal of Cancer Research and Clinical Oncology.